ライフサイエンスコーパス: ITT population

1 estimated cost were also compared (modified ITT population).

2 , 356; lifitegrast, 355 (intention-to-treat [ITT] population).

3 nsive care unit (ICU) stay (intent-to-treat [ITT] population).

4 The remaining 390 lesions constituted the ITT population.

5 he coprimary end points of PFS and OS in the ITT population.

6 d at least one dose and were included in the ITT population.

7 .35 to 0.95) and 0.58 (0.36 to 0.92) for the ITT population.

8 All randomised patients were included in the ITT population.

9 4371 patients were included in the modified ITT population.

10 ays after first dose in the intent-to-treat (ITT) population.

11 e analyses were based on an intent-to-treat (ITT) population.

12 ndomized and constitute the intent-to-treat (ITT) population.

13 -2.68% to 2.95%]) in the intention-to-treat (ITT) population.

14 ference 5.96%p [0.16 to 11.76], p=0.044) and ITT populations (-2.57%p [-6.68 to 1.54], p=0.215, vs -8

15 enrolled, and 41 in each group comprised the ITT population; 33 participants received opicinumab and

16 the endarterectomy group (119 vs 72 events; ITT population, 5-year cumulative risk 15.2% vs 9.4%, HR

17 2%, 97.5% CI 0.2-30.3; p=0.024) and modified ITT populations (53 of 103 [51%] vs 36 of 101 [36%]; 15.

18 In the ITT population, 79.3% of solithromycin patients and 79.7

19 In the micro-ITT population, 80.3% of solithromycin patients and 79.1

20 In the ITT population, 84.6% of solithromycin patients and 88.6

21 In the ITT population, a non-significant reduction in incidence

22 he cure rate was comparable at day 42 in the ITT population (AM-PQP, 94.4% vs AL, 93.1%).

23 in the modified intention-to-treat (modified ITT) population (analysed according to their randomly as

24 d out on the basis of an intention-to-treat (ITT) population and a full-analysis set (FAS).

25 up and 33 in the placebo group comprised the ITT population, and 30 and 27 comprised the mITT populat

26 analysed in the modified intention-to-treat (ITT) population (any randomised patient who received at

27 een the opicinumab and placebo groups in the ITT population at week 24.

28 transplantation need in the intent-to-treat (ITT) population at day 180 (P = 0.087).

29 complete response in the intention-to-treat (ITT) population at the end of treatment.

30 the observation group were excluded from the ITT population because they did not meet post-surgery in

31 Re-review of all patients in the ITT population by the clinical events committee identifi

32 nts withdrew immediately and, therefore, the ITT population comprised 1710 patients.

33 The modified ITT population comprised 274 patients assigned to mepoli

34 The ITT population comprised 70 patients randomly assigned t

35 The modified ITT population consisted of 12 patients in the placebo g

36 The ITT population consisted of all patients who received on

37 The ITT populations consisted of 65 patients who received mu

38 The ITT population included 188 patients with FMS, 78% of wh

39 In the ITT population, median PFS was 7.9, 8.3, and 7.3 months

40 noninferiority in ECR in the microbiological ITT population (micro-ITT) and determination of investig

41 Median survival in the ITT population (n=815 in both groups) was 15.8 months (I

42 tically significant for the intent-to-treat (ITT) population on the basis of diary cards (primary ana

43 In the ITT population, overall survival was improved with atezo

44 showed a trend for improved survival in the ITT population (P =.125).

45 In the modified intention-to-treat (ITT) population, PFS-6 was increased from 42.6% with TMZ

46 follow-up of 1.9 years (IQR 0.9-2.5) in the ITT population, recurrence events were reported in 136 (

47 In the ITT population, rhIL-11 significantly decreased the requ

48 in the intention-to-treat (ITT) and modified ITT populations; safety was assessed in the safety popul

49 ot meet post-surgery inclusion criteria; the ITT population thus consisted of 361 patients in the vit

50 dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin.

51 m first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients)

52 nced magnetic resonance imaging scans of the ITT population was 35% (8% complete response [CR], 27% p

53 ORR in the intention-to-treat (ITT) population was 17% (nine of 54).

54 The intention-to-treat (ITT) and modified ITT populations were included in primary and safety anal

55 ere done in the modified intention-to-treat (ITT) population, which consisted of all patients who rec